Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis
Open accessAbstract
The B cell lymphoma 6 (BCL6) transcriptional repressor is a master regulator of the germinal center (GC) B cell program, required for their unique proliferative and stress tolerant phenotype. Most B cell lymphomas arise from GC B cells and are dependent on the continued or deregulated expression of BCL6 to maintain their survival. The actions of BCL6 in B cells involve formation of distinct chromatin modifying complexes that silence specific promoter and enhancer networks, respectively. The same biochemical mechanisms are maintained in malignant lymphoma cells. Targeted inhibition of these BCL6 functions has emerged as the basis for rational design of lymphoma therapies and combinatorial regimens. In this review, we summarize recent advances on BCL6 mechanisms of action and the deregulation of its target gene networks in lymphoma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
BCL6 is a non-enzymatic oncogenic driver of several B cell malignancies, including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma.
“Bcl6 is a non-enzymatic oncogenic driver of several B cell malignancies, diffuse large B cell lymphoma (DlBcl) and follicular lymphoma (Hatzi and Melnick 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Hatzi and Melnick 2014
Pathologically increased BCL6 expression, as a result of somatic BCL6 translocation, exonic mutation, promoter mutation, or mutations in regulatory pathways, is a common driver of B cell malignancies.
“Pathologically increased BCL6 expression, as a result of somatic BCL6 translocation, exonic mutation, promoter mutation, or mutations in regulatory pathways, is a common driver of B cell malignancies16.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [16]
BCL6 acts as a master transcriptional repressor enabling rapid expansion of germinal center B cells and tolerance to genomic instability caused by hypermutation of immunoglobulin genes and class switch recombination.
“BCL6 acts as a master transcriptional repressor enabling rapid expansion of germinal center (GC) B cells and tolerance to genomic instability caused by hypermutation of the immunoglobulin genes and class switch recombination16.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651 · see citing works
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,514 · see citing works
Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma
Compagno, M., Lim, W., Grunn, A., Nandula, S., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,116 · see citing works
Davis, R. E., Brown, K. D., Siebenlist, U. K., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,053 · see citing works
Wright, G. W., Tan, B. K., Rosenwald, A., Hurt, E. H., Wiestner, A. U., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,039 · see citing works
Germinal-Center Organization and Cellular Dynamics
Allen, C. D. C., Okada, T., & Cyster, J. G. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.009 · Cited by 986 · see citing works
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949 · see citing works
Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6
Dent, A. L., Shaffer, A. L., Yu, X., Allman, D., & Staudt, L. M. (1997) · Science · doi:10.1126/science.276.5312.589 · Cited by 945 · see citing works
Shaffer, A. L., Yu, X., He, Y., Boldrick, J. C., Chan, E. P., & Staudt, L. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00020-0 · Cited by 879 · see citing works
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation
Ye, B. H., Cattoretti, G., Shen, Q. “., Zhang, J., Hawe, N., de Waard, R., Leung, C. C., Nouri-Shirazi, M. A., Orazi, A., Chaganti, R. S. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0697-161 · Cited by 820 · see citing works
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses
Linterman, M. A., Beaton, L., Yu, D., Ramiscal, R. R., Srivastava, M., Hogan, J. J., Verma, N. K., Smyth, M. J., Rigby, R. J., & Vinuesa, C. G. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091738 · Cited by 803 · see citing works
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · see citing works
Molecular Analysis of the T(14;18) Chromosomal Translocation in Malignant Lymphomas
Weiss, L. M., Warnke, R. A., Sklar, J. L., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711053171904 · Cited by 696 · see citing works
Alterations of a Zinc Finger-Encoding Gene, BCL-6 , in Diffuse Large-Cell Lymphoma
Ye, B. H., Lista, F., Lo‐Coco, F., Knowles, D. M., Offit, K., Chaganti, R. S. K., & Dalla‐Favera, R. (1993) · Science · doi:10.1126/science.8235596 · Cited by 682 · see citing works
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla‐Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 680 · see citing works
Savage, K. J. J., Johnson, N. A., Ben‐Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660 · see citing works
BCL-6 protein is expressed in germinal-center B cells
Cattoretti, G., Chang, C., Cechova, K., Zhang, J., Ye, B., Falini, B., Louie, D., Offit, K., CHAGANTI, R. S. K., & Dalla‐Favera, R. (1995) · Blood · doi:10.1182/blood.v86.1.45.bloodjournal86145 · Cited by 564 · see citing works
Frequent inactivation of A20 in B-cell lymphomas
Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., Niwa, A., Chen, Y., Nakazaki, K., Nomoto, J., et al. (2009) · Nature · doi:10.1038/nature07969 · Cited by 553 · see citing works
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 529 · see citing works
Kerfoot, S. M., Yaari, G., Patel, J. R., Johnson, K. L., Gonzalez, D. G., Kleinstein, S. H., & Haberman, A. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.024 · Cited by 494 · see citing works
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry
Dominguez-Sola, D., Victora, G. D., Ying, C. Y., Phan, R. T., Saito, M., Nussenzweig, M. C., & Dalla‐Favera, R. (2012) · Nature Immunology · doi:10.1038/ni.2428 · Cited by 485 · see citing works
BCoR, a novel corepressor involved in BCL-6 repressionPreprint
Huynh, K. D., Fischle, W., Verdin, E. M., & Bardwell, V. J. (2000) · Genes & Development · doi:10.1101/gad.14.14.1810 · Cited by 475 · see citing works
Kitano, M., Moriyama, S., Ando, Y., Hikida, M., Mori, Y., Kurosaki, T., & Okada, T. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.025 · Cited by 412 · see citing works
Saito, M., Gao, J., Basso, K., Kitagawa, Y., Smith, P. M., Bhagat, G., Pernis, A. B., Pasqualucci, L., & Dalla‐Favera, R. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.011 · Cited by 386 · see citing works
Cattoretti, G., Pasqualucci, L., Ballon, G., Tam, W., Nandula, S. V., Shen, Q., Mo, T., Murty, V. V., & Dalla-Favera, R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.037 · Cited by 383 · see citing works
Direct Repression of <i>prdm1</i> by Bcl-6 Inhibits Plasmacytic Differentiation
Tunyaplin, C., Shaffer, A. L., Angelin-Duclos, C. D., Yu, X., Staudt, L. M., & Calame, K. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1158 · Cited by 376 · see citing works
AID is required for germinal center–derived lymphomagenesis
Pasqualucci, L., Bhagat, G., Janković, M., Compagno, M., Smith, P. M., Muramatsu, M., Honjo, T., Morse, H. C., Nussenzweig, M. C., & Dalla‐Favera, R. (2007) · Nature Genetics · doi:10.1038/ng.2007.35 · Cited by 376 · see citing works
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
Pasqualucci, L., Compagno, M., Houldsworth, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052204 · Cited by 370 · see citing works
Gearhart, M. D., Corcoran, C. M., Wamstad, J. A., & Bardwell, V. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00630-06 · Cited by 352 · see citing works
Phan, R. T., Saito, M., Basso, K., Niu, H., & Dalla-Favera, R. (2005) · Nature Immunology · doi:10.1038/ni1245 · Cited by 343 · see citing works
MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation
Fujita, N., Jaye, D. L., Geigerman, C., Akyildiz, A., Mooney, M. R., Boss, J. M., & Wade, P. A. (2004) · Cell · doi:10.1016/j.cell.2004.09.014 · Cited by 328 · see citing works
The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT
Huynh, K. D., & Bardwell, V. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202197 · Cited by 311 · see citing works
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas
Duan, S., C̆ermák, L., Pagan, J. K., Rossi, M., Martinengo, C., di Celle, P. F., Chapuy, B., Shipp, M. A., Chiarle, R., & Pagano, M. (2011) · Nature · doi:10.1038/nature10688 · Cited by 295 · see citing works
Niu, H., Ye, B. H., & Dalla‐Favera, R. (1998) · Genes & Development · doi:10.1101/gad.12.13.1953 · Cited by 292 · see citing works
Polo, J. M., Dell’Oso, T., Ranuncolo, S. M., Cerchietti, L. C. A., Beck, D. B., da Silva, G. F., Privé, G. G., Licht, J. D., & Melnick, A. M. (2004) · Nature Medicine · doi:10.1038/nm1134 · Cited by 291 · see citing works
Self-citationA Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288 · see citing works
Self-citationMechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain
Ahmad, K. F., Melnick, A. M., Lax, S. A., Bouchard, D., Liu, J., Kiang, C. L., Mayer, S., Takahashi, S., Licht, J. D., & Privé, G. G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00454-4 · Cited by 282 · see citing works
Self-citationRanuncolo, S. M., Polo, J. M., Dierov, J., Singer, M., Kuo, T., Greally, J., Green, R., Carroll, M., & Melnick, A. (2007) · Nature Immunology · doi:10.1038/ni1478 · Cited by 278 · see citing works
Self-citationYe, B. H., Rao, P. H., Chaganti, R. S. K., & Dalla‐Favera, R. (1993) · PubMed · Cited by 243 · see citing works
Ci, W., Polo, J. M., Cerchietti, L. C. A., Shaknovich, R., Wang, L., Yang, S. N., Ye, K. Q., Farinha, P., Horsman, D. E., Gascoyne, R. D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193037 · Cited by 240 · see citing works
Self-citationMutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas
Tam, W., Gomez, M. F., Chadburn, A., Lee, J. W., Chan, W. C., & Knowles, D. M. (2006) · Blood · doi:10.1182/blood-2005-09-3778 · Cited by 229 · see citing works
Sánchez, C., Sánchez, I., Demmers, J., Rodriguez, P., Strouboulis, J., & Vidal, M. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600275-mcp200 · Cited by 223 · see citing works
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 221 · see citing works
Iqbal, J., Greiner, T. C., Patel, K., Davé, B. J., Smith, L. M., Ji, J. H., Wright, G. W., Sanger, W. G., Pickering, D. L., Jain, S., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404856 · Cited by 216 · see citing works
Vasanwala, F. H., Kusam, S., Toney, L. M., & Dent, A. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1922 · Cited by 199 · see citing works
BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
Saito, M., Novak, U., Piovan, E., Basso, K., Sumazin, P., Schneider, C., Crespo, M., Shen, Q. “., Bhagat, G., Califano, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903854106 · Cited by 197 · see citing works
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
Ying, C. Y., Dominguez-Sola, D., Fabi, M., Lorenz, I. C., Hussein, S., Bansal, M., Califano, A., Pasqualucci, L., Basso, K., & Dalla‐Favera, R. (2013) · Nature Immunology · doi:10.1038/ni.2688 · Cited by 187 · see citing works
Hatzi, K., Jiang, Y., Huang, C., Garrett-Bakelman, F. E., Gearhart, M. D., Γιαννοπούλου, Ε., Zumbo, P., Kirouac, K. N., Bhaskara, S., Polo, J. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.06.016 · Cited by 186 · see citing works
Self-citationHarris, M. B., Chang, C.-C., Berton, M. T., Danial, N. N., Zhang, J., Kuehner, D., Ye, B. H., Kvatyuk, M., Pandolfi, P. P., Cattoretti, G., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7264 · Cited by 186 · see citing works
Lee, C. H., Melchers, M., Wang, H., Torrey, T. A., Slota, R., Qi, C., Kim, J. Y., Lugar, P., Kong, H. J., Farrington, L. A., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051450 · Cited by 186 · see citing works
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Cerchietti, L. C. A., Yang, S. N., Shaknovich, R., Hatzi, K., Polo, J. M., Chadburn, A., Dowdy, S. F., & Melnick, A. M. (2008) · Blood · doi:10.1182/blood-2008-07-168773 · Cited by 183 · see citing works
Self-citationStructure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer
Ghetu, A. F., Corcoran, C. M., Cerchietti, L., Bardwell, V. J., Melnick, A., & Privé, G. G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.026 · Cited by 168 · see citing works
Self-citationCerchietti, L. C. A., Lopes, E. C., Yang, S. N., et al. (2009) · Nature Medicine · doi:10.1038/nm.2059 · Cited by 161 · see citing works
Scheeren, F. A., Naspetti, M., Diehl, S. A., Schotte, R., Nagasawa, M., Wijnands, E., Gimeno, R., Vyth‐Dreese, F. A., Blom, B., & Spits, H. (2005) · Nature Immunology · doi:10.1038/ni1172 · Cited by 160 · see citing works
Parekh, S. S., Polo, J. M., Shaknovich, R., Juszczyński, P., Lev, P. R., Ranuncolo, S. M., Yin, Y., Klein, U., Cattoretti, G., Favera, R. D., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069575 · Cited by 146 · see citing works
Self-citationHuang, C., Hatzi, K., & Melnick, A. M. (2013) · Nature Immunology · doi:10.1038/ni.2543 · Cited by 139 · see citing works
Self-citationPolo, J. M., Juszczyński, P., Monti, S., Cerchietti, L. C. A., Ye, K. Q., Greally, J. M., Shipp, M. A., & Melnick, A. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611399104 · Cited by 135 · see citing works
Self-citationBCL6 positively regulates AID and germinal center gene expression via repression of miR-155
Basso, K., Schneider, C., Shen, Q. “., Holmes, A. B., Setty, M. N., Leslie, C. S., & Dalla‐Favera, R. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20121387 · Cited by 131 · see citing works
Cerchietti, L. C. A., Hatzi, K., Caldas-Lopes, E., Yang, S. N., Figueroa, M. E., Morin, R. D., Hirst, M., Mendez, L., Shaknovich, R., Cole, P. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42869 · Cited by 119 · see citing works
Self-citationBCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells
Ranuncolo, S. M., Polo, J. M., & Melnick, A. (2008) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2008.02.003 · Cited by 116 · see citing works
Self-citationDNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas
Lai, A. Y., Fatemi, M., Dhasarathy, A., Malone, C. C., Sobol, S. E., Geigerman, C., Jaye, D. L., Mav, D., Shah, R., Li, L., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100204 · Cited by 101 · see citing works
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
Chevallier, N., Corcoran, C. M., Lennon, C., et al. (2003) · Blood · doi:10.1182/blood-2003-06-2081 · Cited by 79 · see citing works
The human BCL6 transgene promotes the development of lymphomas in the mouse
Baron, B. W., Anastasi, J., MONTAG, A. G., Huo, D., Baron, R. M., Karrison, T. G., Thirman, M. J., Subudhi, S. K., Chin, R., Felsher, D. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406138101 · Cited by 73 · see citing works
Kim, D. W., Kim, D. W., Chang, W., Choe, J., Kim, J., Park, C.-S., Song, K., & Lee, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102297 · Cited by 70 · see citing works
CtBP Is an Essential Corepressor for BCL6 Autoregulation
Mendez, L., Polo, J. M., Yu, J., Krupski, M., Ding, B. B., Melnick, A. M., & Ye, B. H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01400-07 · Cited by 69 · see citing works
Self-citationPanagopoulos, D., Victoratos, P., Alexiou, M. V., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13253-13261.2004 · Cited by 66 · see citing works
Recognition DNA Sequence of a Novel Putative Transcription Factor, BCL6
Kawamata, N., Takashi, M. I. K. I., Ohashi, K., et al. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2468 · Cited by 65 · see citing works
Juszczyński, P., Chen, L., O'Donnell, E., Polo, J. M., Ranuncolo, S. M., Dalla‐Favera, R., Melnick, A. M., & Shipp, M. A. (2009) · Blood · doi:10.1182/blood-2009-02-204362 · Cited by 62 · see citing works
Self-citationBCL-6 Negatively Regulates Expression of the NF-κB1 p105/p50 Subunit
Li, Z., Wang, X., Yu, R. Y.-L., Ding, B. B., Yu, J., Dai, X.-M., Naganuma, A., Stanley, E. R., & Ye, B. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.205 · Cited by 53 · see citing works
Tan, D. E. K., Foo, J. N., Bei, J., Chang, J., Peng, R., Zheng, X., Wei, L., Huang, Y., Lim, W. Y., Li, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2666 · Cited by 48 · see citing works
Moriyama, M., Yamochi, T., Semba, K., Akiyama, T., & Mori, S. (1997) · Oncogene · doi:10.1038/sj.onc.1201084 · Cited by 46 · see citing works
Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells
Polo, J. M., Ci, W., Licht, J. D., & Melnick, A. M. (2008) · Blood · doi:10.1182/blood-2008-01-131813 · Cited by 43 · see citing works
Self-citationRamachandrareddy, H., Bouska, A. C., Shen, Y., Ji, M. H., Rizzino, A., Chan, W. C., & McKeithan, T. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004962107 · Cited by 33 · see citing works
Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas
Cerchietti, L. C. A., Polo, J. M., da Silva, G. F., Farinha, P., Shaknovich, R., Gascoyne, R. D., Dowdy, S. F., & Melnick, A. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5817 · Cited by 30 · see citing works
Self-citationDupont, T., Dong, Z., Yang, S., et al. (2012) · Blood · doi:10.1182/blood.v120.21.64.64 · Cited by 4 · see citing works
Čuljković, B., Fernando, T. M., Yang, S., et al. (2013) · Blood · doi:10.1182/blood.v122.21.3785.3785 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dynamics of B cells in germinal centres
De Silva, N. S., & Klein, U. (2015) · Nature Reviews Immunology · doi:10.1038/nri3804 · Cited by 1,084 · see citing works
BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms
Hatzi, K., Nance, J. P., Kroenke, M. A., Bothwell, M., Haddad, E. K., Melnick, A., & Crotty, S. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141380 · Cited by 261 · see citing works
Self-citationSmall-molecule-induced polymerization triggers degradation of BCL6
Słabicki, M., Yoon, H., Koeppel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2925-1 · Cited by 270 · see citing works
Béguelin, W., Teater, M., Gearhart, M. D., Calvo Fernández, M. T., Goldstein, R. L., Cárdenas, M. G., Hatzi, K., Rosen, M., Shen, H., Corcoran, C. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.006 · Cited by 254 · see citing works
Self-citationChemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207 · see citing works
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85795 · Cited by 176 · see citing works
Self-citationMondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H.-Y., Chu, C.-S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0116 · Cited by 167 · see citing works
Self-citationBunting, K. L., Soong, T. D., Singh, R., Jiang, Y., Béguelin, W., Poloway, D. W., Swed, B. L., Hatzi, K., Reisacher, W., Teater, M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.012 · Cited by 141 · see citing works
Self-citationTBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate
Venturutti, L., Teater, M., Zhai, A., Chadburn, A., Babiker, L., Kim, D., Béguelin, W., Lee, T. C., Kim, Y., Chin, C. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.049 · Cited by 127 · see citing works
Self-citationBellenie, B. R., Cheung, K.-M. J., Varela, A., Pierrat, O. A., Collie, G. W., Box, G. M., Bright, M. D., Gowan, S., Hayes, A., Rodrigues, M. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02076 · Cited by 74 · see citing works
Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0840 · Cited by 70 · see citing works
Polymerization of ZBTB transcription factors regulates chromatin occupancy
Park, P. M. C., Park, J., Brown, J., Hunkeler, M., Roy Burman, S. S., Donovan, K. A., Yoon, H., Nowak, R. P., Słabicki, M., Ebert, B. L., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.06.010 · Cited by 22 · see citing works
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 10 · see citing works
“Bcl6 is a non-enzymatic oncogenic driver of several B cell malignancies, diffuse large B cell lymphoma (DlBcl) and follicular lymphoma (Hatzi and Melnick 2014).”
- Authors
- Hatzi, K., & Melnick, A.
- Affiliations
- Weill Cornell Medicine (US)
- Corresponding author
- Melnick, Ari
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 20
- Issue
- 6
- Pages
- 343-352
- ISSN
- 1471-4914 (ISSN-L)
- PMC
- PMC4041810
- OpenAlex
- W1966652028
- Cited by
- 183
- References
- 76
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 8 · 2023: 14 · 2022: 17 · 2021: 19 · 2020: 18 · 2019: 16 · 2018: 19 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 6
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA104348, R01CA143032)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- BCL6, germinal center B cells, B-cell lymphoma, lymphomagenesis, transcriptional repression, chromatin-modifying complexes, enhancer silencing, promoter silencing, BCL6 inhibitors, lymphoma treatment
- MeSH terms
- Cell Survival, DNA-Binding Proteins, Enhancer Elements, Genetic, Gene Expression Regulation, Humans, Immune System, Promoter Regions, Genetic, Gene Expression Regulation, Neoplastic, Lymphoma, B-Cell, Epigenesis, Genetic, Proto-Oncogene Proteins c-bcl-6, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
